华海药业股票讨论区

Zhejiang Huahai Pharmaceutical's share price drop doesn't align with its EPS growth and revenue increase, hinting at other influencing factors. Last year's performance suggests unresolved issues, and long-term share price weakness could be a negative sign or a potential turnaround for contrarian investors.

Analysts are more bearish on Zhejiang Huahai Pharmaceutical's future, reducing revenue and EPS estimates. The downgrade, coupled with high debt, hints at a potential business downturn.

Investors are hesitant to pay more for Zhejiang Huahai Pharmaceutical's stock due to expected limited future growth. The current P/E ratio mirrors these assumptions.

Zhejiang Huahai Pharmaceutical's efficient reinvestment has driven substantial earnings growth. Market fluctuations notwithstanding, the company's management has successfully utilized capital, as evidenced by its higher-than-average ROE.